Carlsbad, CA—March 30, 2017 (BUSINESS WIRE)
Ra Medical Systems, Inc., makers of excimer lasers and catheters for cardiovascular and dermatological diseases, has received FDA (CFDA) approval for the Pharos Excimer Laser to treat psoriasis, vitiligo, and other skin diseases in The People’s Republic of China.
Ra Medical Systems is actively seeking distributors in China.
Pharos has more than a decade of proven clinical success in the United States, Middle East, and select markets in Asia, with millions of treatments performed.
Psoriasis is the second most common skin disorder which affects approximately 1 in every 49 people, or about 2.02% of the population.
Approval in China widens Pharos’ geographic scope and opens new opportunity to provide best-in-class therapy for China’s estimated 26 million psoriasis sufferers.
It also gives new hope to China’s estimated 13 million vitiligo patients, many of whom have been told there are no treatment options for their disease.
“2017 will be a pivotal year for Ra Medical Systems’ dermatology division as we capitalize on the approvals to sell Pharos in China and the European Union. The CFDA approval in China and CE mark for Europe set the stage for helping millions of patients and driving growth for the company” said co-founder and CEO Dean Irwin.
“Medicine is modernizing in China, new hospitals and clinics are opening up, and millions of dermatology patients are gaining access to treatment for their diseases for the first time in their lives. The Pharos is now in China, at the right time, in the right place,” added Jeffrey Kraws, President.
About Ra Medical Systems
Ra Medical Systems was founded in 2002 to commercialize excimer lasers for the treatment of dermatologic and cardiovascular diseases. Its flagship product, Pharos, launched in 2004 and revolutionized the dermatology world with its technology and game-changing business model.
Today, Ra Medical Systems continues to make history as it commercializes the DABRA catheter and cardiovascular system.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act
With the exception of the historical information contained in this release, the matters described here may contain forward-looking statements, including statements that involve risk and uncertainties that may individually or mutually impact the matters herein and cause actual results, events and performance to differ materially.
For more information contact:
Jeffrey Kraws, President
In the US: 1 877 635 1800, Internationally: +1 760 804 1648